Figure S1. Analysis of the influence of TF on HUVECs. (A) Groups of HUVECs ($2x10^5$) were incubated with recombinant TF (0, 0.5 and 2 U/ml) or PAR2-AP (SLIGKV; 20 μM), or with recombinant TF (0.5 U/ml) that was pre-incubated for 60 min with 10H10 antibody (20 μg/ml). Cells were also pre-incubated for 60 min with AIIB2 antibody (20 μg/ml), prior to addition of TF. The cells were harvested after 24 h, total RNA was isolated, and Inhibitor of CDK $p16^{INKa}$ mRNA quantified by RT-qPCR, against β-actin (n=5). Groups of HUVECs ($2x10^5$) were incubated with recombinant TF (0, 0.5 and 2 U/ml). The cells were harvested after 24 h, total RNA was isolated and (B) the mRNA for CDK interacting protein/Wildtype p53-activated fragment $p21^{CIP1/WAF1}$ was analysed by end-point RT-PCR and (C) quantified, against β-actin (n=3). Additionally, (B) Cyclin D1 mRNA was analysed by end-point RT-PCR, and (D) quantified against β-actin (n=3). (E) HUVECs ($1x10^5$) were incubated with recombinant TF (0, 0.5 and 2 U/ml) and cell numbers were determined at 24 h using crystal violet staining (n=5). TF, tissue factor; PAR2, protease-activated receptor 2; HUVEC, human umbilical vein endothelial cell.



Figure S2. Groups of HDBECs ($1x10^5$) were transfected with the pGL3-promoter vector containing the E2F enhancer sequence. Groups of cells were pre-incubated for 60 min with ribocilib (10 nM) and one group were then treated with recombinant TF (0.5 U/ml). The luciferase activity was measured within 24 h (n=4). TF, tissue factor; E2F, early region 2 binding factor.



Figure S3. Groups of HDBECs ($1x10^5$) were incubated overnight with recombinant TF (0, 0.5 and 2 U/ml) or PAR2-AP (SLIGKV; 20 μM), or with recombinant TF (0.5 U/ml) that was pre-incubated for 60 min with HTF-1 antibody (20 μg/ml). Cells were also pre-incubated for 60 min with SAM11 antibody (20 μg/ml), prior to the addition of TF. The cells were then fixed and stained with crystal violet and images were captured using a Nikon TS microscope (magnification, 10x). A stage micrometre was imaged to indicate the size of the images. Images are representative of 3 separate experiments. The samples are (A) untreated, (B) treated with TF (0.5 U/ml), (C) treated with TF (2 U/ml), (D) treated with TF (0.5 U/ml) pre-incubated with HTF-1 antibody. Other sets of cells were (E) pre-incubated with SAM11 antibody prior to addition of TF (0.5 U/ml) or (F) treated with PAR2-AP (20 μM). TF, tissue factor; PAR2, protease-activated receptor 2.